{"commentary":{"count":15,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":11,"youtube":3,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03068455\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CheckMate 915","nct_id":"NCT03068455","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-915-nct03068455. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"CheckMate 915","arms":[{"description":"Specified Dose on Specified Days","label":"nivolumab + ipilimumab","type":"EXPERIMENTAL"},{"description":"Specified Dose on Specified Days","label":"nivolumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-02-02","type":"ACTUAL"},"conditions":["Melanoma"],"enrollment":{"count":1844,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"nivolumab","type":"BIOLOGICAL"},{"name":"ipilimumab","type":"BIOLOGICAL"}],"last_update":"2021-09-20","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-06-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Recurrence-free Survival (RFS) - All Randomized Participants","timeFrame":"From randomization to Primary Completion Date (up to approximately 3 years)"},{"measure":"Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level < 1%","timeFrame":"From randomization to Primary Completion Date (up to approximately 3 years)"}],"references":[{"citation":"Long GV, Tang H, Desai K, Wang S, Del Vecchio M, Larkin J, Ritchings C, Huang SP, Baden J, Balli D, Chang H, Fusaro G, Tenney D, Dolfi S, Weber J. Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915. J Immunother Cancer. 2025 Jul 11;13(7):e012034. doi: 10.1136/jitc-2025-012034.","pmid":"40645660","type":"DERIVED"},{"citation":"Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Munoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). J Clin Oncol. 2023 Jan 20;41(3):517-527. doi: 10.1200/JCO.22.00533. Epub 2022 Sep 26.","pmid":"36162037","type":"DERIVED"},{"citation":"Yoshino T, Oki E, Misumi T, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Sakamoto Y, Shiozawa M, Nishi M, Horiuchi T, Yamagishi H, Sakamoto J, Mizushima T, Ohtsu A, Mori M. Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial. J Clin Oncol. 2022 Oct 10;40(29):3419-3429. doi: 10.1200/JCO.21.02628. Epub 2022 May 5.","pmid":"35512259","type":"DERIVED"}],"start_date":{"date":"2017-04-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma","url":"https://clinicaltrials.gov/study/NCT03068455"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-915-nct03068455"}